CD8A and non-small cell lung carcinoma: In patients with NSCLC, those with an increased peripheral PD-1+ CD8+ (double-positive PD-1 and CD8) clonality after ICPi treatment, and with a high PD-1+ CD8+ diversity pre-ICPi exhibited a better response and a longer PFS, as compared to those with low clonality and diversity [16].